BioMonde

US-based wound care firm BioMonde has launched its patented biosurgical medical device, BioBag, in the US.

The debridement product for patient use is currently available for clinicians across all 50 US states, DC and Puerto Rico.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

BioBag uses all the benefits of biosurgery in an easy-to-use contained dressing and was developed for the debridement of various wounds, including pressure ulcers, neuropathic ulcers, venous stasis ulcers and non-healing traumatic or surgical wounds.

The company said BioBag is currently the only FDA cleared contained biosurgical dressing on the market.

BioMonde product manager Katy Nicell said: "Many of the debridement options currently available do not actively, and selectively, remove bacterial burden and all devitalised tissue from a wound. Biosurgery is unique.

See Also:

"BioBag allows clinicians to debride wounds with precision, while ensuring containment and patient acceptance."

"The wound size does not increase past the level of damaged tissue and nothing unviable is left behind meaning that effective proliferation can take place."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BioBag allows clinicians to debride wounds with precision, while ensuring containment and patient acceptance.

BioMonde CEO Gareth Kempson said: "Historically, bio-surgery was reserved for the most challenging wounds that were not responding to conventional treatment.

"In Europe and the UK, we have proven that the early inclusion of BioBag into the routine debridement practice of non-healing wounds, enables rapid results to be achieved in a cost-efficient manner."

BioMonde manufactured and supplied Larval Therapy in Europe and the UK. The company’s manufacturing facilities are in Bridgend, Wales, Hamburg, Germany and Gainesville, Florida.

Image: BioMonde has launched its patented biosurgical medical device BioBag. Photo: courtesy of Business Wire.